Results for tag: "Duchenne Muscular Dystrophy Drug"

Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder that affects the muscles and is caused by a mutation in the dystrophin gene. It is the most common form of muscular dystrophy and is characterized by progressive muscle weakness and loss of muscle mass. Treatment for DMD is limited to supportive care and the use of certain drugs to slow the progression of the disease. Central Nervous System (CNS) drugs are used to treat the symptoms of DMD, such as muscle spasms, pain, and fatigue. These drugs can also help to improve the quality of life of those affected by the disorder. The DMD drug market is a rapidly growing segment of the CNS drug market. It is estimated that the global DMD drug market will reach $2.5 billion by 2027, driven by the increasing prevalence of DMD and the development of new drugs. Several companies are involved in the development and commercialization of DMD drugs, including Sarepta Therapeutics, Pfizer, GlaxoSmithKline, and Novartis. Show Less Read more